MENU
+Compare
SKYE
Stock ticker: NASDAQ
AS OF
Aug 22, 04:59 PM (EDT)
Price
$3.28
Change
-$0.27 (-7.61%)
Capitalization
101.95M

SKYE Skye Bioscience Forecast, Technical & Fundamental Analysis

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California... Show more

SKYE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for SKYE with price predictions
Aug 21, 2025

SKYE sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for SKYE moved above the 200-day moving average on July 30, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 66 cases where SKYE's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on August 21, 2025. You may want to consider a long position or call options on SKYE as a result. In of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

SKYE moved above its 50-day moving average on August 21, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SKYE advanced for three days, in of 241 cases, the price rose further within the following month. The odds of a continued upward trend are .

SKYE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 10-day moving average for SKYE crossed bearishly below the 50-day moving average on August 19, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SKYE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for SKYE entered a downward trend on August 21, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.334) is normal, around the industry mean (19.773). P/E Ratio (3.566) is within average values for comparable stocks, (54.197). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.633). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (300.579).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SKYE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SKYE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
SKYE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BKQNF4.14N/A
N/A
Bank of Queensland Ltd.
KMBIF14.33N/A
N/A
Kambi Group LTD.
NICXF0.30N/A
N/A
Nicox S.A.
LFCBY16.57N/A
N/A
Lifco AB
BRST0.04N/A
-8.97%
Broad Street Realty Inc.

SKYE and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, SKYE has been loosely correlated with CRBP. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if SKYE jumps, then CRBP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SKYE
1D Price
Change %
SKYE100%
+1.43%
CRBP - SKYE
48%
Loosely correlated
+5.21%
JANX - SKYE
40%
Loosely correlated
-3.50%
VKTX - SKYE
34%
Loosely correlated
-0.12%
ABOS - SKYE
32%
Poorly correlated
-3.55%
RGNX - SKYE
32%
Poorly correlated
+0.50%
More